Roche Has Over Five Weight-Loss Companion Medicines, CEO Says

Roche has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical industry’s fastest-growing market. Speaking to Bloomberg Television, Schinecker said combination therapy could help treat kidney, liver and heart disease. Chapters: 00:00:00 - Intro 00:00:00 - Roche CEO Thomas Schinecker Targeting GLP-1 Obesity Drugs 00:02:06 - Thomas Schinecker on M&As, deal plans for Roche 00:02:25 - Roche CEO on early-stage data, research reports 00:04:13 - Thomas Schinecker on suggestions Roche would need to do a deal in order to acquire amylin asset, potentially via Danish biotech Zealand Pharma 00:05:33 - Roche CEO Schinecker on US elections, drug pricing, opportunities 00:06:40 - Roche CEO On anti-cancer medications, due diligence, clinical development -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more. Connect with Bloomberg Television on: X:   / bloombergtv   Facebook:   / bloombergtelevision   Instagram:   / bloombergtv   Connect with Bloomberg Business on: X:   / business   Facebook:   / bloombergbusiness   Instagram:   / bloombergbusiness   TikTok: https://www.tiktok.com/@bloombergbusi... Reddit:   / bloomberg   LinkedIn:   / bloomberg-news   More from Bloomberg: Bloomberg Radio:   / bloombergradio   Bloomberg Surveillance:   / bsurveillance   Bloomberg Politics:   / bpolitics   Bloomberg Originals:   / bbgoriginals   Watch more on YouTube: Bloomberg Technology:    / @bloombergtechnology   Bloomberg Originals:    / @business   Bloomberg Quicktake:    / @bloombergquicktake   Bloomberg Espanol:    / @bloomberg_espanol   Bloomberg Podcasts:    / @bloombergpodcasts